Adage Capital Partners’s Sarepta Therapeutics SRPT Stock Holding History

Adage Capital Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-175,000	Closed	-$21.3M	–	935
2024 Q4	$21.3M	Sell	175,000 -100,000	-36%	-$12.3M	0.04%	431
2024 Q3	$34.3M	Sell	275,000 -125,000	-31%	-$17.3M	0.06%	304
2024 Q2	$63.2M	Sell	400,000 -70,000	-15%	-$8.99M	0.12%	182
2024 Q1	$60.8M	Buy	+470,000	New	+$57.6M	0.11%	193
2023 Q4	–	Sell	-560,000	Closed	-$67.9M	–	926
2023 Q3	$67.9M	Sell	560,000 -95,000	-15%	-$10.7M	0.15%	150
2023 Q2	$75M	Buy	655,000 +254,650	+64%	+$32.8M	0.16%	145
2023 Q1	$55.2M	Sell	400,350 -274,650	-41%	-$35.6M	0.12%	192
2022 Q4	$87.5M	Sell	675,000 -210,000	-24%	-$24.3M	0.21%	118
2022 Q3	$97.8M	Sell	885,000 -380,000	-30%	-$38.3M	0.24%	97
2022 Q2	$94.8M	Buy	1,265,000 +250,000	+25%	+$18.4M	0.22%	99
2022 Q1	$79.3M	Buy	1,015,000 +365,000	+56%	+$28M	0.15%	143
2021 Q4	$58.5M	Buy	650,000 +250,000	+63%	+$21.4M	0.11%	194
2021 Q3	$37M	Buy	400,000 +40,247	+11%	+$3.1M	0.07%	273
2021 Q2	$28M	Buy	+359,753	New	+$27.3M	0.05%	355
2021 Q1	–	Sell	-300,000	Closed	-$51.1M	–	1023
2020 Q4	$51.1M	Sell	300,000 -550,000	-65%	-$81.5M	0.11%	197
2020 Q3	$119M	Sell	850,000 -250,000	-23%	-$38M	0.3%	69
2020 Q2	$176M	Sell	1,100,000 -925,000	-46%	-$126M	0.45%	42
2020 Q1	$198M	Buy	2,025,000 +937,670	+86%	+$107M	0.59%	25
2019 Q4	$140M	Sell	1,087,330 -637,626	-37%	-$64.4M	0.34%	66
2019 Q3	$130M	Buy	1,724,956 +524,956	+44%	+$62M	0.32%	75
2019 Q2	$182M	Sell	1,200,000 -450,000	-27%	-$54.7M	0.45%	49
2019 Q1	$197M	Sell	1,650,000 -700,144	-30%	-$90M	0.49%	48
2018 Q4	$256M	Buy	2,350,144 +1,050,144	+81%	+$131M	0.71%	28
2018 Q3	$210M	Buy	1,300,000 +243,389	+23%	+$33.3M	0.47%	46
2018 Q2	$140M	Buy	1,056,611 +956,611	+957%	+$90.2M	0.32%	74
2018 Q1	$7.41M	Buy	+100,000	New	+$6.67M	0.02%	600

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners's SRPT Position: Q1 2025 in Review

Adage Capital Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 175,000 shares — an estimated $21.3M sold.

Adage Capital Partners first reported a position in SRPT in Q1 2018 and held it in 26 quarters. The position peaked at $256M in Q4 2018. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Adage Capital Partners reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Adage Capital Partners sold 175,000 Sarepta Therapeutics shares in Q1 2025, an estimated $21.3M.
Adage Capital Partners first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 26 quarters.
Adage Capital Partners's Sarepta Therapeutics position peaked at $256M in Q4 2018.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.